• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

晚期基底细胞癌中的表皮生长因子受体抑制剂

Epidermal growth factor receptor inhibitor in advanced basal cell carcinoma.

作者信息

Amirabadi Amir, Alami Amirhosein, Ahanchian Hamid, Ariaee Nazila, Moazzen Nasrin

机构信息

Department of Internal Medicine Azad University of Medical Sciences Mashhad Iran.

Department of Biology Azad University of Medical Sciences Mashhad Iran.

出版信息

Clin Case Rep. 2021 Mar 24;9(5):e04021. doi: 10.1002/ccr3.4021. eCollection 2021 May.

DOI:10.1002/ccr3.4021
PMID:34084482
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8142310/
Abstract

Cetuximab can be used for the treatment of advanced basal cell carcinoma, especially when the patient cannot tolerate routine chemotherapy. Future studies are needed to confirm it.

摘要

西妥昔单抗可用于治疗晚期基底细胞癌，尤其是当患者无法耐受常规化疗时。未来需要进行研究加以证实。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1b5/8142310/bf6aae1961a7/CCR3-9-e04021-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1b5/8142310/bf6aae1961a7/CCR3-9-e04021-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1b5/8142310/bf6aae1961a7/CCR3-9-e04021-g002.jpg

相似文献

1
Epidermal growth factor receptor inhibitor in advanced basal cell carcinoma.晚期基底细胞癌中的表皮生长因子受体抑制剂
Clin Case Rep. 2021 Mar 24;9(5):e04021. doi: 10.1002/ccr3.4021. eCollection 2021 May.
2
Update of cetuximab for non-melanoma skin cancer.西妥昔单抗在非黑素瘤皮肤癌中的应用进展。
Expert Opin Biol Ther. 2014 Feb;14(2):271-6. doi: 10.1517/14712598.2013.876406. Epub 2014 Jan 6.
3
Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer.靶向表皮生长因子受体的嵌合单克隆抗体西妥昔单抗治疗晚期非黑色素瘤皮肤癌
Open Access Maced J Med Sci. 2017 Dec 31;6(1):152-155. doi: 10.3889/oamjms.2018.022. eCollection 2018 Jan 25.
4
Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.表皮生长因子受体抑制剂西妥昔单抗的不良反应
Acta Dermatovenerol Croat. 2016 Apr;24(1):70-2.
5
Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.表皮生长因子受体抗体治疗不可切除的皮肤鳞状细胞癌——病例系列。
Eur J Dermatol. 2013 Sep-Oct;23(5):658-62. doi: 10.1684/ejd.2013.2153.
6
Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer.对于一名表皮生长因子受体阳性、雌激素受体阴性、孕激素受体阴性且人表皮生长因子受体2阴性（三阴性）乳腺癌患者的皮肤转移灶，紫杉醇与西妥昔单抗联合治疗取得了显著疗效。
Anticancer Drugs. 2007 Aug;18(7):835-7. doi: 10.1097/CAD.0b013e3280adc8e0.
7
Cetuximab in non-melanoma skin cancer.西妥昔单抗在非黑素瘤皮肤癌中的应用。
Expert Opin Biol Ther. 2012 Jul;12(7):949-56. doi: 10.1517/14712598.2012.681374. Epub 2012 Apr 23.
8
Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.表皮生长因子受体靶向治疗 III 期和 IV 期头颈部癌症。
Curr Oncol. 2010 Jun;17(3):37-48. doi: 10.3747/co.v17i3.520.
9
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.西妥昔单抗：一种表皮生长因子受体嵌合型人鼠单克隆抗体。
Drugs Today (Barc). 2005 Feb;41(2):107-27. doi: 10.1358/dot.2005.41.2.882662.
10
Cetuximab in refractory skin cancer treatment.西妥昔单抗用于难治性皮肤癌治疗。
J Cancer. 2012;3:257-61. doi: 10.7150/jca.3491. Epub 2012 Jun 7.

引用本文的文献

1
The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies.西妥昔单抗在非黑色素瘤皮肤癌中的作用：临床证据与新兴策略综述
Curr Treat Options Oncol. 2025 Jul 9. doi: 10.1007/s11864-025-01335-3.
2
Images in Immunotherapy and Precision Oncology: Advanced Basal Cell Carcinoma.免疫治疗与精准肿瘤学中的影像：晚期基底细胞癌
J Immunother Precis Oncol. 2024 Aug 19;7(3):201-204. doi: 10.36401/JIPO-23-47. eCollection 2024 Aug.

本文引用的文献

1
The PROCESS 2018 statement: Updating Consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) guidelines.PROCESS 2018 声明：更新外科手术病例系列报告的共识首选报告规范（PROCESS）指南。
Int J Surg. 2018 Dec;60:279-282. doi: 10.1016/j.ijsu.2018.10.031. Epub 2018 Oct 22.
2
Update of cetuximab for non-melanoma skin cancer.西妥昔单抗在非黑素瘤皮肤癌中的应用进展。
Expert Opin Biol Ther. 2014 Feb;14(2):271-6. doi: 10.1517/14712598.2013.876406. Epub 2014 Jan 6.
3
Induction cisplatin-based chemotherapy and following radiotherapy in locally advanced basal cell carcinoma of the skin.
局部晚期皮肤基底细胞癌的顺铂诱导化疗及后续放疗
Acta Oncol. 2012 Sep;51(7):952-4. doi: 10.3109/0284186X.2012.670265. Epub 2012 Apr 4.
4
Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years.40岁以下人群中基底细胞癌和鳞状细胞癌的发病率。
JAMA. 2005 Aug 10;294(6):681-90. doi: 10.1001/jama.294.6.681.
5
Epidemiology of actinic keratoses and squamous cell carcinoma.光化性角化病与鳞状细胞癌的流行病学
J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):4-7. doi: 10.1067/mjd.2000.103342.
6
Radiation therapy in skin cancer. A historical perspective and current applications.皮肤癌的放射治疗。历史回顾与当前应用。
Dermatol Surg. 1997 Nov;23(11):1089-93. doi: 10.1111/j.1524-4725.1997.tb00454.x.
7
Status of curettage and desiccation in the treatment of primary basal cell carcinoma.刮除术与干燥法治疗原发性基底细胞癌的现状
J Am Acad Dermatol. 1984 Feb;10(2 Pt 1):285-7. doi: 10.1016/s0190-9622(84)80220-0.
8
Aggressive-growth basal cell carcinoma in young adults.青年侵袭性生长基底细胞癌
Arch Dermatol. 1991 Nov;127(11):1663-7.
9
Mohs Micrographic Surgery for skin cancer.用于皮肤癌的莫氏显微外科手术。
Australas J Dermatol. 1991;32(3):159-64. doi: 10.1111/j.1440-0960.1991.tb01783.x.